We're committed to providing you with the very best cancer care, and your safety continues to be a top priority. With this in mind, we’ve put in place many new procedures, including a limited visitor policy. This is just one more way of ensuring your safety and that of our staff. Read more
Chairman, Department of Epidemiology and Biostatistics
Dr. Begg has research interests spanning cancer epidemiology and statistical methods that are applicable to clinical research more broadly. In recent years he has been developing methods to identify etiologically distinct cancer sub-types, statistical tests of clonal relatedness of pairs of tumors, and more recently, efforts to detect clinically relevant signals from rare somatic mutations. Dr. Begg is Chair of the Department of Epidemiology and Biostatistics that conducts quantitative research across the cancer spectrum (link to dept website here). Dr. Begg has also served since 2014 as Editor-in-Chief of the international scholarly journal, Clinical Trials.
Mauguen A, Zabor EC, Thomas NE, Berwick M, Seshan VE, Begg CB. Defining cancer subtypes with distinctive etiologic profiles: an application to the epidemiology of melanoma. Journal of the American Statistical Association 2017;112:54-63. PMCID: PMC5460661.
Mauguen A, Seshan VE, Ostrovnaya I, Begg CB. Estimating the probability of clonal relatedness of pairs of tumors in cancer patients. Biometrics. 2018 Mar;74(1):321-330. PMCID: PMC5677588.
Begg CB, Ostrovnaya I, Geyer FC, Papanastasiou AD, Ng CKY, Sakr RA, Bernstein JL, BurkeKA, King TA, Piscuoglio S, Mauguen A, Orlow I, Weigelt B, Seshan VE, Morrow M, Reis-Filho JS. Contralateral breast cancers: Independent cancers or metastases? International Journal of Cancer 2018;142:347-356.
Chakraborty S, Arora A, Begg CB, Shen R. Using somatic variant richness to mine signals from rare variants in the cancer genome. Nat Comm. 2019 Dec 3;10(1):5506. PMCID: PMC6890761.
Begg CB. In defense of p-values. JNCI Cancer Spectr. 2020 Feb 26;4(2): pkaa012. PMID: 32373778; PMCID: PMC7191891.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Colin Begg discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at firstname.lastname@example.org.